Efficacy of glucagon‐like peptide‐1 receptor agonists for psoriasis: An updated systematic review and meta‐analysis

JDDG: Journal der Deutschen Dermatologischen GesellschaftEarly View CLINICAL LETTER Efficacy of glucagon-like peptide-1 receptor agonists for psoriasis: An updated systematic review and meta-analysis Su-Chi Ku, Su-Chi Ku Department of General Medicine, Taipei Medical University Hospital, Taipei, TaiwanSearch for more papers by this authorHua-Ching Chang, Corresponding Author Hua-Ching Chang [email protected] orcid.org/0000-0003-3608-1394 Department of Dermatology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan Department of Dermatology, Taipei Medical University Hospital, Taipei, Taiwan Research Center of Big Data and Meta-Analysis, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan Correspondence: Hua-Ching Chang, MD, MS, Department of Dermatology, Taipei Medical University Hospital, No. 252, Wuxing Street, Xinyi District, Taipei City, 110, Taiwan. Email: [email protected]Search for more papers by this author Su-Chi Ku, Su-Chi Ku Department of General Medicine, Taipei Medical University Hospital, Taipei, TaiwanSearch for more papers by this authorHua-Ching Chang, Corresponding Author Hua-Ching Chang [email protected] orcid.org/0000-0003-3608-1394 Department of Dermatology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan Department of Dermatology, Taipei Medical University Hospital, Taipei, Taiwan Research Center of Big Data and Meta-Analysis, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan Correspondence: Hua-Ching Chang, MD, MS, Department of Dermatology, Taipei Medical University Hospital, No. 252, Wuxing Street, Xinyi District, Taipei City, 110, Taiwan. Email: [email protected]Search for more papers by this author First published: 02 June 2024 https://doi.org/10.1111/ddg.15431Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1Chiu H-Y, Wang T-S, Chen P-H, et al. Psoriasis in Taiwan: From epidemiology to new treatments. Dermatologica Sinica. 2018; 36: 115-123. 10.1016/j.dsi.2018.06.001 Web of Science®Google Scholar 2Schön MP, Wilsmann-Theis D. Current developments and perspectives in psoriasis. J Dtsch Dermatol Ges. 2023; 21: 363-372. 10.1111/ddg.15033 Google Scholar 3Mehdi SF, Pusapati S, Anwar MS, et al. Glucagon-like peptide-1: A multi-faceted anti-inflammatory agent. Front Immunol. 2023; 14:1148209. 10.3389/fimmu.2023.1148209 CASPubMedWeb of Science®Google Scholar 4Chang G, Chen B, Zhang L. Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: A systematic review and meta-analysis of prospective cohort and before-after studies. J Dermatolog Treat. 2022; 33: 1299-1305. 10.1080/09546634.2021.1882658 CASPubMedWeb of Science®Google Scholar 5Sun X, Cai X, Liu L, et al. Effect of Different Types of Hypoglycemic Medications on Psoriasis: An Analysis of Current Evidence. Dermatology. 2023; 239: 299-313. 10.1159/000528026 CASPubMedGoogle Scholar 6Ahern T, Tobin AM, Corrigan M, et al. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: A prospective cohort study. J Eur Acad Dermatol Venereol. 2013; 27: 1440-1443. 10.1111/j.1468-3083.2012.04609.x CASPubMedWeb of Science®Google Scholar 7Buysschaert M, Baeck M, Preumont V, et al. Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: A prospective case-series study. Br J Dermatol. 2014; 171: 155-161. 10.1111/bjd.12886 CASPubMedWeb of Science®Google Scholar 8Xu X, Lin L, Chen P, et al. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study. Diabetes Res Clin Pract. 2019; 150: 167-173. 10.1016/j.diabres.2019.03.002 CASPubMedWeb of Science®Google Scholar 9Nicolau J, Nadal A, Sanchís P, et al. Effects of liraglutide among patients living with psoriasis and obesity. Med Clin (Barc). 2023; 161: 293-296. 10.1016/j.medcli.2023.05.021 CASPubMedGoogle Scholar 10Faurschou A, Gyldenløve M, Rohde U, et al. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients–a randomized placebo-controlled trial. J Eur Acad Dermatol Venereol. 2015; 29: 555-559. 10.1111/jdv.12629 CASPubMedWeb of Science®Google Scholar 11Lin L, Xu X, Yu Y, et al. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: A randomized-controlled trial. J Dermatolog Treat. 2022; 33: 1428-1434. 10.1080/09546634.2020.1826392 CASPubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation